These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 24831287)

  • 21. Feasibility of conducting a primary prevention trial of low-dose aspirin for major adverse cardiovascular events in older people in Australia: results from the ASPirin in Reducing Events in the Elderly (ASPREE) pilot study.
    Nelson MR; Reid CM; Ames DA; Beilin LJ; Donnan GA; Gibbs P; Johnston CI; Krum H; Storey E; Tonkin A; Wolfe R; Woods R; McNeil JJ
    Med J Aust; 2008 Jul; 189(2):105-9. PubMed ID: 18637782
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Individualized Risk Communication and Outreach for Primary Cardiovascular Disease Prevention in Community Health Centers: Randomized Trial.
    Persell SD; Brown T; Lee JY; Shah S; Henley E; Long T; Luther S; Lloyd-Jones DM; Jean-Jacques M; Kandula NR; Sanchez T; Baker DW
    Circ Cardiovasc Qual Outcomes; 2015 Nov; 8(6):560-6. PubMed ID: 26555123
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force.
    Wolff T; Miller T; Ko S
    Ann Intern Med; 2009 Mar; 150(6):405-10. PubMed ID: 19293073
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identifying opportunities to improve aspirin utilization for the primary prevention of cardiovascular disease in a regional health care system.
    VanWormer JJ; Miller AW; Rezkalla H
    WMJ; 2014 Oct; 113(5):190-5; quiz 196. PubMed ID: 25739162
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Elderly Japanese Patients with Atherosclerotic Risk Factors: Subanalysis of a Randomized Clinical Trial (JPPP-70).
    Sugawara M; Goto Y; Yamazaki T; Teramoto T; Oikawa S; Shimada K; Uchiyama S; Ando K; Ishizuka N; Murata M; Yokoyama K; Uemura Y; Ikeda Y;
    Am J Cardiovasc Drugs; 2019 Jun; 19(3):299-311. PubMed ID: 30565155
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.
    Ridker PM; Cook NR; Lee IM; Gordon D; Gaziano JM; Manson JE; Hennekens CH; Buring JE
    N Engl J Med; 2005 Mar; 352(13):1293-304. PubMed ID: 15753114
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Age-Related Trajectories of Cardiovascular Risk and Use of Aspirin and Statin Among U.S. Adults Aged 50 or Older, 2011-2018.
    Rhee TG; Kumar M; Ross JS; Coll PP
    J Am Geriatr Soc; 2021 May; 69(5):1272-1282. PubMed ID: 33598936
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials.
    Seidu S; Kunutsor SK; Sesso HD; Gaziano JM; Buring JE; Roncaglioni MC; Khunti K
    Cardiovasc Diabetol; 2019 Jun; 18(1):70. PubMed ID: 31159806
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial.
    Fowkes FG; Price JF; Stewart MC; Butcher I; Leng GC; Pell AC; Sandercock PA; Fox KA; Lowe GD; Murray GD;
    JAMA; 2010 Mar; 303(9):841-8. PubMed ID: 20197530
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aspirin in primary prevention. Meta-analysis stratified by baseline cardiovascular risk.
    Masson G; Lobo M; Masson W; Molinero G
    Arch Cardiol Mex; 2020; 90(3):293-299. PubMed ID: 32952164
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low-dose aspirin and upper gastrointestinal bleeding in primary versus secondary cardiovascular prevention: a population-based, nested case-control study.
    Lin KJ; De Caterina R; García Rodríguez LA
    Circ Cardiovasc Qual Outcomes; 2014 Jan; 7(1):70-7. PubMed ID: 24254886
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aspirin is associated with reduced cardiovascular and all-cause mortality in type 2 diabetes in a primary prevention setting: the Fremantle Diabetes study.
    Ong G; Davis TM; Davis WA
    Diabetes Care; 2010 Feb; 33(2):317-21. PubMed ID: 19918016
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk.
    Greving JP; Buskens E; Koffijberg H; Algra A
    Circulation; 2008 Jun; 117(22):2875-83. PubMed ID: 18506010
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bleeding Risks With Aspirin Use for Primary Prevention in Adults: A Systematic Review for the U.S. Preventive Services Task Force.
    Whitlock EP; Burda BU; Williams SB; Guirguis-Blake JM; Evans CV
    Ann Intern Med; 2016 Jun; 164(12):826-35. PubMed ID: 27064261
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Primary prevention aspirin use in high-risk patients: A pharmacist intervention and comparison of risk stratification tools.
    Coon SA; Brooks AD; Wolff SE
    J Am Pharm Assoc (2003); 2017; 57(5):585-590. PubMed ID: 28811088
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of updated recommendations on acetylsalicylic acid use for primary prevention of cardiovascular disease in Canada: a population-based survey.
    Khalili M; Lepeytre F; Guertin JR; Goupil R; Troyanov S; Bouchard J; Madore F
    CMAJ Open; 2020; 8(1):E41-E47. PubMed ID: 31992558
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of a Geographic Information System to create treatment groups for group-randomized community trials: The Minnesota Heart Health Program.
    Krzyzanowski B; Manson SM; Eder MM; Kne L; Oldenburg N; Peterson K; Hirsch AT; Luepker RV; Duval S
    Trials; 2019 Mar; 20(1):185. PubMed ID: 30922358
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aspirin for primary prevention of CVD: are the right people using it?
    VanWormer JJ; Greenlee RT; McBride PE; Peppard PE; Malecki KC; Che J; Nieto FJ
    J Fam Pract; 2012 Sep; 61(9):525-32. PubMed ID: 23000660
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is There Still a Role for Aspirin in Primary Prevention in Women in 2020?
    Sulaica EM; Asias-Dinh BD; Wanat MA; Birtcher KK
    Curr Atheroscler Rep; 2020 Jun; 22(8):34. PubMed ID: 32556683
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.